🇺🇸 FDA
Patent

US 8383583

Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors

granted A61KA61K31/13A61K31/505

Quick answer

US patent 8383583 (Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/13, A61K31/505, A61K31/7056, A61K38/21